These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27075128)

  • 1. Interferon beta-1a-induced morphea.
    Bezalel SA; Strober BE; Ferenczi K
    JAAD Case Rep; 2015 Jan; 1(1):15-7. PubMed ID: 27075128
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a.
    Ebrahimimonfared M; Ganji A; Zahedi S; Nourbakhsh P; Ghasami K; Mosayebi G
    CNS Neurol Disord Drug Targets; 2018; 17(2):113-118. PubMed ID: 29589548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta1a or glatiramer acetate compared with untreated patients.
    Jansson A; Ernerudh J; Kvarnström M; Ekerfelt C; Vrethem M
    Mult Scler; 2003 Oct; 9(5):440-5. PubMed ID: 14582766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
    Nischwitz S; Faber H; Sämann PG; Domingues HS; Krishnamoorthy G; Knop M; Müller-Sarnowski F; Yassouridis A; Weber F
    Acta Neurol Scand; 2014 Jul; 130(1):46-52. PubMed ID: 24571587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response.
    Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A; Tilea B; Tiu C
    CNS Neurol Disord Drug Targets; 2017; 16(1):93-101. PubMed ID: 27306062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-beta inhibits human Th17 cell differentiation.
    Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
    J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
    Link J
    Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
    Perini P; Facchinetti A; Bulian P; Massaro AR; Pascalis DD; Bertolotto A; Biasi G; Gallo P
    Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment.
    Franciotta D; Zardini E; Bergamaschi R; Andreoni L; Cosi V
    J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):123-6. PubMed ID: 12486283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).
    Rudick RA; Simonian NA; Alam JA; Campion M; Scaramucci JO; Jones W; Coats ME; Goodkin DE; Weinstock-Guttman B; Herndon RM; Mass MK; Richert JR; Salazar AM; Munschauer FE; Cookfair DL; Simon JH; Jacobs LD
    Neurology; 1998 May; 50(5):1266-72. PubMed ID: 9595973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon beta induces T-helper 2 immune deviation in MS.
    Kozovska ME; Hong J; Zang YC; Li S; Rivera VM; Killian JM; Zhang JZ
    Neurology; 1999 Nov; 53(8):1692-7. PubMed ID: 10563614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis.
    Ahn J; Feng X; Patel N; Dhawan N; Reder AT
    Front Biosci; 2004 May; 9():1547-55. PubMed ID: 14977566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of CCL27 and IL-11 in Multiple Sclerosis Patients Treated with Interferon-β and Glatiramer Acetate.
    Ebrahimi Monfared M; Shapoori S; Mosayebi G; Khansarinejad B; Ghazavi A; Rezagholizamenjany M; Ganji A
    Neuroimmunomodulation; 2019; 26(6):301-306. PubMed ID: 31935737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 17 receptor in multiple sclerosis patients treated with interferon β-1a.
    Michałowska-Wender G; Biernacka-Łukanty J; Lasik Z; Jernas L; Wender M
    Folia Neuropathol; 2011; 49(2):138-41. PubMed ID: 21845543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis].
    Leussink VI; Warnke C; Tackenberg B; Wiendl H; Kieseier BC
    Nervenarzt; 2015 Apr; 86(4):483-90. PubMed ID: 25833401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of IFN-β1a and IFN-β1b treatment on the expression of cytokines, inducible NOS (NOS type II), and myelin proteins in animal model of multiple sclerosis.
    Lubina-Dąbrowska N; Stepień A; Sulkowski G; Dąbrowska-Bouta B; Langfort J; Chalimoniuk M
    Arch Immunol Ther Exp (Warsz); 2017 Aug; 65(4):325-338. PubMed ID: 28299403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis.
    Monzani F; Meucci G; Caraccio N; Saviozzi M; Casolaro A; Moscato G; Lombardo F; Mosti S; Scagnolari C; Bruschi F; Antonelli G; Ferrannini E; Murri L
    J Interferon Cytokine Res; 2002 Jul; 22(7):773-81. PubMed ID: 12184915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
    Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appropriate use of interferon beta-1a in multiple sclerosis.
    Jacobs L; Brownscheidle CM
    BioDrugs; 1999 Mar; 11(3):155-63. PubMed ID: 18031126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.